lab-on-a-chip (LOC) Market Growth, Share, Analysis and Trends by 2028

 The global lab-on-a-chip (LOC) market size is expected to reach USD 12.85 Billion at a steady CAGR of 10.6% in 2028, according to latest analysis by Emergen Research. Lab-on-a-chip market revenue growth is being steadily driven by increase in demand for point of care testing, rising prevalence of chronic diseases, and growing application of genomics and proteomics in cancer research. is widely adopted for drug discoveries and biomarker. Rise in demand for personalized medicines is further driving Lab-on-a-chip market revenue growth, and the trend is expected to continue going ahead. The global e-prescribing market is expected to rise with an impressive CAGR and generate the highest revenue by 2026

The report provides a 360-degree overview of the market, listing various factors restricting, propelling, and obstructing the market in the forecast duration. The report also provides additional information such as interesting insights, key industry developments, detailed segmentation of the market, list of prominent players operating in the market, and other e-prescribing market trends. The report is available for sale on the company website.

Emergen Research has segmented the global lab-on-a-chip (LOC) market on the basis of product type, technology, application, end-use, and region:

  • Product Type Outlook (Revenue, USD Billion; 2018–2028)
    • Software
    • Reagents & Consumables
    • Instruments
  • Technology Outlook (Revenue, USD Billion; 2018–2028)
    • Microarrays
    • Microfluidics
  • Application Outlook (Revenue, USD Billion; 2018–2028)
    • Proteomics
    • Genomics
    • Drug Discovery
    • Diagnostics
  • End-use Outlook (Revenue, USD Billion; 2018–2028)
    • Diagnostic Labs
    • Hospitals
    • Biotechnology & Pharmaceutical Companies
    • Academic & Research Institutes

In June 2020, Sengenics launched multi-antigen COVID-19 biochip test, ImmuSAFE, which is a lab-based biochip test that uses the company’s patented KREX protein folding technology. ImmuSAFE enables the identification of target epitopes, titres, and Ig class/sub-class (IgG, IgA, IgM; IgG1-4) of antibodies produced at various stages of COVID-19 infection; from disease development, initial exposure, and post-recovery to post-vaccination.

Application of microfluidics has made it possible to shift conventional laboratory procedures to lab-on-a-chip. Microfluidics aims to reduce mistakes in cost management and offer good return on investment. Microfluidics has been used extensively in the manufacturing of a wide variety of consumer products.

In proteomics, lab-on-a-chip offers the opportunity to perform protein analysis. Proteomics also show great potential for protein crystallization, which is an important field that reveals 3D structures of a protein. Application of lab-on-a-chip can help researchers simultaneously control all possible parameters in the fastest way, which enables crystallization of a protein.

Lab-on-a-chip market revenue in Asia Pacific is expected to register fastest growth rate during the forecast period owing to surge in development of healthcare infrastructure, high prevalence of diseases such as renal diseases and cardiovascular diseases, and growth of the R&D facilities. In addition, rapidly increasing global geriatric population and rising demand for regenerative medicines are key factors driving growth of the market in the region.

Key players in the market include Becton, Dickinson and Company, PerkinElmer, Inc., Bio-Rad Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific, Siemens Healthcare, Abaxis Inc., Roche Diagnostics, Abbott Laboratories, and Danaher Corporation.

Popular posts from this blog

Common Excuses Addicts Give to Avoid Treatment

Singing bowl healing properties